<DOC>
	<DOCNO>NCT02775435</DOCNO>
	<brief_summary>This study carboplatin paclitaxel nano particle albumin-bound paclitaxel ( nab-paclitaxel ) without pembrolizumab ( MK-3475 , KEYTRUDA® ) adult first line metastatic squamous non-small cell lung cancer ( NSCLC ) . The primary hypothesis treatment pembrolizumab prolongs : 1 ) Progression-free Survival ( PFS ) Response Evaluation Criteria Solid Tumors version 1.1 ( RECIST 1.1 ) assess blinded central image vendor compare placebo , 2 ) Overall Survival ( OS ) .</brief_summary>
	<brief_title>A Study Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With Without Pembrolizumab ( MK-3475 ) Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer ( MK-3475-407/KEYNOTE-407 )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Has histologically cytologically confirm diagnosis stage IV ( M1a M1bAmerican Joint Committee Cancer [ AJCC ] 7th edition ) squamous NSCLC . Has measurable disease base RECIST 1.1 determine local site investigator/radiology assessment . Has receive prior systemic treatment metastatic NSCLC . Has provide tumor tissue location radiate prior biopsy . Has life expectancy least 3 month . Has performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) Performance Status . Has adequate organ function . If female childbearing potential , willing use adequate method contraception course study 120 day last dose study drug . If male female partner ( ) childbearing potential , must agree use adequate method contraception start first dose study drug 120 day last dose study drug . Males pregnant partner must agree use condom ; additional method contraception require pregnant partner . Has nonsquamous histology NSCLC . Is currently participate receive study therapy participate study investigational agent receive study therapy use investigational device within 4 week prior administration pembrolizumab . Before first dose study drug : ) Has receive prior systemic cytotoxic chemotherapy metastatic disease ; b ) Has receive targeted biological antineoplastic therapy ( e.g. , erlotinib , crizotinib , cetuximab ) metastatic disease ; c ) Has major surgery ( &lt; 3 week prior first dose ) . Received radiation therapy lung &gt; 30 Gy within 6 month first dose study drug . Completed palliative radiotherapy within 7 day first dose study drug . Is expect require form antineoplastic therapy study . Has receive livevirus vaccination within 30 day plan treatment start . Has know history prior malignancy except participant undergone potentially curative therapy evidence disease recurrence 5 year since initiation therapy . Has know active central nervous system ( CNS ) metastases and/or carcinomatous meningitis . Has preexist peripheral neuropathy ≥ Grade 2 Common Terminology Criteria Adverse Events ( CTCAE ) version 4 criterion . Previously severe hypersensitivity reaction treatment another monoclonal antibody . Has know sensitivity component carboplatin paclitaxel nabpaclitaxel . Has active autoimmune disease require systemic treatment past 2 year . Is chronic systemic steroid . Had prior treatment antiprogrammed cell death 1 ( antiPD1 ) , program cell death ligand 1 ( PDL1 ) PDL2 agent antibody small molecule target immunoregulatory receptor mechanism . Has participate pembrolizumab trial treat pembrolizumab . Has active infection require therapy . Has know history Human Immunodeficiency Virus ( HIV ) . Has know active Hepatitis B C. Active Hepatitis B . Is , time signing informed consent , regular user ( include `` recreational use '' ) illicit drug recent history ( within last year ) substance abuse ( include alcohol ) . Has interstitial lung disease history pneumonitis require oral intravenous glucocorticoid assist management . Is pregnant breastfeeding , expect conceive father child study drug require duration contraception last dose study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PD1</keyword>
	<keyword>PD-1</keyword>
	<keyword>PDL1</keyword>
	<keyword>PD-L1</keyword>
</DOC>